SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis
暂无分享,去创建一个
[1] Miguel Park,et al. Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions , 2021, Annals of Allergy, Asthma & Immunology.
[2] A. Peters,et al. COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol. , 2021, Allergy and asthma proceedings.
[3] E. Walsh,et al. Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccines in Patients With Hypersensitivity to First Dose , 2021, Open forum infectious diseases.
[4] J. Bernstein,et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach , 2021, The Journal of Allergy and Clinical Immunology: In Practice.
[5] Paige G. Wickner,et al. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing , 2021, The Journal of Allergy and Clinical Immunology: In Practice.
[6] C. Akin,et al. Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome , 2021, The Journal of Allergy and Clinical Immunology. in Practice.
[7] A. Ramsey,et al. Administration of a Second Dose of the Moderna COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports , 2021, Annals of Internal Medicine.
[8] M. Triggiani,et al. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM) , 2021, The Journal of Allergy and Clinical Immunology: In Practice.
[9] M. Castells,et al. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis , 2021, Journal of Allergy and Clinical Immunology.
[10] Paige G. Wickner,et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach , 2020, The Journal of Allergy and Clinical Immunology: In Practice.
[11] M. Triggiani,et al. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions , 2020, Journal of Allergy and Clinical Immunology.
[12] S. Spector,et al. Adverse reactions to vaccines practice parameter 2012 update. , 2012, The Journal of allergy and clinical immunology.
[13] J. Ring,et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients , 2008, Allergy.